Blog
Featured post
Generating data gravity
This post is the first of six deep dives I plan to do into the significant technology challenges we have solved at Truveta using the power of AI to enable healthcare research...
Monitoring GLP-1 RA prescription trends
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) increased throughout the first quarter of 2024 (+20.9% increase in March 2024 compared to December...
Real-time monitoring of viral gastroenteritis: April 2024
Norovirus and rotavirus are significant contributors to gastrointestinal infections worldwide, creating risk for patient populations and strain on the healthcare system. Truveta...
New insights from family history can shed light on prostate cancer
You probably know someone who will be diagnosed with prostate cancer in their lifetime. 1 in 8 men will develop prostate cancer, with a higher risk in Black and African American...
Truveta Research and collaborators receive ISPOR 2024 Best General Poster Research Presentation award
Truveta Research and collaborators Anupam B. Jena, MD, PhD and Christopher Worsham, MD, MPH received the ISPOR 2024 Best General Poster Research Presentation Award for their...
Truveta Data used in new study shows women and Black patients less likely to receive catheter-based treatment for pulmonary embolism
Recently, researchers presented new insights from a continued analysis of the REAL-PE study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2024 meeting....
Rod Hochman, MD, president and CEO of Providence, is new Truveta Board of Directors Chair
Today Truveta welcomes Rod Hochman, MD, president and CEO of Providence, as its new Board of Directors Chair. Truveta’s Board of Directors ensures Truveta is operating in pursuit...
Real-world prescribing of lecanemab in the United States
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue,...
Baseline A1C and BMI trends for people with type 2 diabetes receiving first-time GLP-1 RA prescriptions
Authors: Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA,...